The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Bio Inc ( ($ETNB) ) has released its Q4 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors. 89bio Inc., a ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday, February 24th. HC Wainwright analyst P.

1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...

Analysts at StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on ...

Hvivo anticipates that full-scale Hmpv human challenge trials (HCTs) could commence in the second half of 2025 ...